Maria Kallmeyer Quoted in BioSpace Article About Biopharma Concerns Over New H-1B Visa Fee
Maria Kallmeyer, national co-chair of the Quarles & Brady Immigration & Mobility Practice Group who is based in the firm’s Chicago office, was quoted in a BioSpace article on biopharma concerns over the Trump administration’s new $100,000 H-1B visa petition fee, which could hinder the industry’s ability to attract and retain foreign-born talent.
An excerpt:
Because of the new petition fee, employers will reconsider hiring people who need H-1Bs, according to Maria Kallmeyer, partner and national chair of the immigration and mobility practice group at Quarles. She told BioSpace that $100,000 “is a completely unreasonable fee” that’s out of line with previous H-1B costs. This type of visa sponsorship has typically cost companies a few thousand dollars.
…
“I think that companies are going to think twice about it, because a fee that high is going to be very difficult for them to pay for,” Kallmeyer said. “Maybe some companies will pay for it for some very particular people that they need, but I think it’s cost prohibitive for sure.”
Please visit our Federal Policy Watch: Monitoring White House Developments page for more insight about navigating changes at the federal level.